Keeping an Eye Out for Immunotherapy Toxicity: A Case of Unilateral Ptosis Caused by Ipilimumab/Nivolumab Therapy

J Immunother Precis Oncol. 2024 May 2;7(2):126-129. doi: 10.36401/JIPO-23-44. eCollection 2024 May.

Abstract

Despite ocular adverse events from immune checkpoint inhibitors being uncommon, they are still important complications to be aware of. We present the case of metastatic melanoma on ipilimumab/nivolumab in a patient who developed immunotherapy complications with delayed diagnosis because the only presenting symptom was unilateral ptosis. We reviewed the literature for relevant and important ocular and neurological complications of immune checkpoint inhibitors.

Keywords: immunotherapy; myositis; ocular toxicity.

Publication types

  • Case Reports